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ABSTRACT 
 
Many new drug substances have low aqueous solubility which can cause poor bioavailability after oral 
administration. Solid dispersions are one of the most promising strategies to improve the oral bioavailability of 
poorly water soluble drugs. By reducing drug particle size to the absolute minimum, and hence improving drug 
wettability, bioavailability may be significantly improved. Generally, SDs can be defined as a dispersion of active 
ingredients in molecular, amorphous and/or microcrystalline forms into an inert carrier. The application of solid 
dispersions is a useful method to increase the dissolution rate of drugs. This article is indented to combine literature 
on solid dispersion technology for solubility enhancement with special emphasis on mechanism responsible for the 
same by solid dispersion, various preparation methods and evaluation parameters.  
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Introduction 
 
Oral drug delivery is the simplest and easiest way of 
administered many drugs into the systemic circulation. 
Comparatively oral drug delivery system has other 
drug delivery system patient compliance, greater 
stability, accurate dosage and easy to produce. 
Therefore, most of the new chemical entities (NCEs) 
under research these days are intended to be used as a 
solid dosage form that invent an effective and 
reproducible in vivo plasma concentration after oral 
administration. In fact, most NCEs are poorly water 
soluble drugs, low absorption after oral administration, 
which can distract from the drug’s inherent potency. 
Moreover, most promising NCEs, despite their high 
permeability are generally only absorbed in the upper 
small intestine, absorption being reduced significantly 
after the ileum, showing, therefore, that there is a small 
absorption window [1].  
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Various factor limited the drug absorption from the 
gastrointestinal tract like nature of drug, 
physicochemical properties of drug, gastric empty time 
etc. When drug administrated orally, before it can 
reach to systemic circulation it must be dissolve in 
gastric and/or intestinal fluids. Hence, in 
pharmaceutical research focus on two domain 
enhancing the oral bioavailability of active agents 
include; improving solubility and dissolution rate of 
poorly water-soluble drugs, enhancing permeability of 
poorly water-soluble drugs. Lipid-based delivery 
systems are becoming increasingly popular as carriers 
of drugs because of their ability to bypass some of the 
more resistant chemical and physical barriers 
associated with poorly absorbed drugs [2]. 
Various approaches to beat the poor aqueous solubility 
of drug candidates have been investigated in drug 
research and development such as solid dispersion salt 
formation, prodrug formation, complexation, particle 
size reduction, microemulsions, micelles, liposomes, 
nanoparticles, nanoemulsions, nanosuspensions and 
solid-lipid nanoparticleetc. Solid dispersion is which 
review as one of the most effective strategies to 
enhanced the absorption of poor water soluble 
drugs[3].  
 Solubility 
Solubility is the property of a solid, liquid or gaseous 
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chemical substance called solute to dissolve in solvent 
(solid, liquid or gaseous) to form a homogeneous 
solution of the solute in the solvent. The extent of 
solubility of a substance in a specific solvent is 
measured as the saturation concentration where adding 
more solute does not increase its concentration in the 
solution[4-6]. 
 
Table 1: Solubility. 
Definition Parts of solvent required for one part of solute 
Very soluble <1 
Freely soluble 1- 10 
Soluble 10- 30 
Sparingly soluble 30- 100 
Slightly soluble 100- 1000 
Very slightly soluble 1000- 10,000 
Insoluble >10,000 
 
Mechanism of solubilization[7] 
Drug solubility is the maximum concentration of the 
drug solute dissolved in the solvent under specific 
conditions of temperature, pH and pressure. The 
solubility of weak acids or weak bases varies 
considerably as a fraction of pH. 
For weak acids the total solubility (Cs) is given by the 
expression; 
Cs = [HA] + [A
-
] 
Where [HA] = intrinsic solubility of the non ionized 
acid , [A
-
] = the concentration of its anion 
The anion concentration can be expressed in terms of 
dissociation constant Ka; 
Cs = Co + Ka[Co / H
+
] 
[Co = non- ionized acid concentration] 
This equation indicates that the solubility of weak acid 
increases with the increasing pH. Solubility is higher 
optimal at higher pH. 
Solubility for weak base is given by the expression; 
Cs = Co + Co [H
+ 
/ Ka] 
This equation indicates that solubility of weak base 
decreases with increasing pH. Solubility is optimal at 
lower pH. 
 
Techniques to enhance the solubility 
Solubility improvement techniques can be categorized as under: [2, 8] 
 
Table 2: Techniques to increase the solubility of drugs 
Physical modifications 
a. Particle size reduction 
1. Micrionization 
2. Nanosuspension  Homogenization Wet  milling 
3. Sonocrystallization 
4.Supercritical fluid process 
5. Spray drying 
b. Modification of crystal 
habit 
1. Polymorphs 
2. Pseudopolymorph 
c. Drug dispersion in carriers 
1. Eutectic mixtures 
2. Solid dispersions 
3. Solid solutions 
4. Cryogenic techniques 
Chemical modifications 
a. Change of pH 
b. Use of buffers 
c. Derivatization 
d. Complexation 
e. Salt formation 
Miscellaneous methods 
a. Supercritical fluid process b. Use of adjuvants 
(surfactants, solubilizers, cosolvency, hydrotrophy and novel 
excipients) 
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Solid dispersions: an approach for delivery of 
poorly soluble drugs 
Effective method to improve the solubility and 
bioavailability of poorly water soluble drugs is solid 
dispersions. In 1961, Sekiguchi and Obi first proposed 
the utilization of solid dispersions to increase the 
dissolution and oral absorption of such drugs [9-10]. 
Earlier studies show that solid dispersions systems 
increased the drug dissolution due to improved 
solubility, wet ability and dispersability using 
hydrophobic carriers[9]. The development of solid 
dispersion as a practically viable method and overcame 
the limitations of previous approaches such as a salt 
formation, solubilisation by co solvents and particle 
size reduction. The term solid dispersions refer to a 
group of at least two different components, generally a 
hydrophobic drug and hydrophillic matrix. The matrix 
can be either amorphous or crystalline. The drug can be 
dispersed molecularly, in crystalline particles based on 
their molecular arrangement or in amorphous particles 
(clusters) (11-12). Chieu and Riegelman defined term 
solid dispersions as, "a dispersion involving 
formation of eutectic mixtures of drugs with water 
soluble carrier by melting of their physical 
mixtures"[10, 13]. The dissolution is enhanced by 
dispersing a poorly soluble drug in a highly soluble 
solid hydrophillic matrix [14].  
Mechanism of dissolution of solid dispersions 
The currently accepted range of possible mechanisms 
for enhanced dissolution rate effectively stems from the 
seminal review of various authors. These mechanisms 
include:  
 Surface area is increased.  
 Wetting of drug is improved by direct contact of 
drug with hydrophillic polymers. 
 The drug has higher energy in amorphous state 
than in the crystalline state through which the 
saturated concentration is increased.  
 The saturated concentration around small particles 
is higher than around large particles.  
Therefore, SD improves the bioavailability of poorly 
soluble drugs by increasing the drug dissolution rate 
and their saturated solubility in gastrointestinal fluids 
[15-17] 
Classification of solid dispersions 
1. On the basis of carrier used [1,18] 
First generation solid dispersions:In 1961, Sekiguchi 
and Obi noticed that the formulation of eutectic 
mixtures improved the rate of drug release and, 
consequently, the bioavailability of poor water soluble 
drugs due to small particle size and better wettability. 
Later Levy and Kanig developed solid dispersion 
systems, containing mannitol as carrier, by preparing 
solid solutions through molecular dispersions. The 
observed improvements were attributed to a faster 
carrier dissolution, releasing microcrystals or particles 
of drug. These solid dispersions, which could be 
designed as first generation solid dispersions were 
prepared using crystalline carriers. Crystalline carriers 
include urea and sugars which was the first carrier to 
be employed in solid dispersions. 
Second generation solid dispersions:A second 
generation of solid dispersions contained amorphous 
carriers instead of crystalline carriers. In amorphous 
solid solutions, drug and carrier are totally miscible and 
soluble, originating a homogeneous molecular 
interaction between them. Polymeric carriers have been 
successful, because they are able to originate 
amorphous solid dispersions. They are divided into 
fully synthetic polymers (povidone, 
polyethyleneglycols, polymethacrylates) and natural 
product based polymer (hydroxy propyl methyl 
cellulose, ethylcellulose, hydroxypropyl cellulose, 
starch derivatives). In second generation solid 
dispersions, the drug is in a supersaturated state 
because of forced solubilization in the carrier. 
Third generation solid dispersions:Third generation 
solid dispersions are intended to achieve the highest 
degree of bioavailability for poorly soluble drugs and 
to stabilize the solid dispersion, avoiding drug 
recrystallization. The dissolution profile can be 
improved if the carrier has surface activity or self 
emulsifying properties. The use of surfactants such as 
inulin, inutec SPI, compritol 888 ATO, gelucire and 
poloxamer 407 as carriers was shown to be effective in 
originating high polymorphic purity and enhanced in 
vivo bioavailabillity. 
2. On the basis of the molecular arrangement 
The various types of solid dispersions can be 
distinguished on the basis of the molecular 
arrangement as follows:  
Simple eutectic mixtures:The simple eutectic mixture 
is usually prepared from rapid solidification of fused 
liquid of two components which show complete liquid 
miscibility and negligible solid-solid solubility. 
Thermodynamically, such a system is regarded as an 
intimately blended physical mixture of its two 
crystalline components. When a eutectic composed of a 
poorly soluble drug is exposed to water or GI fluids, 
the carrier may be released into aqueous medium in 
fine crystalline form. The eutectic phase diagram is 
shown in figure 1 [10,19] 
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Figure 1: Eutectic system phase diagram 
 
 
Fig 1:Eutectic system phase diagram 
Solid solutions:In solid solutions, the two components 
crystallize together in homogeneous one-phase system. 
The particle size of drug in a solid solution is reduced 
is reduced to its molecular size. Thus, a solid solution 
can achieve a faster dissolution rate than corresponding 
eutectic mixtures[6] 
These can be further classified according to miscibility 
as: 
Continuous solid solutions:In this, method both the 
components are mixed to each other to obtain miscible 
solid state. The reason may be that the strength of 
bonding between the molecules of each of the 
individual components is weaker than the strength of 
bonding between two components. The soluble carrier 
present in the crystal lattice of the drug may result in 
faster dissolution rate as compared to pure 
compound[20,21]. Figure 2 illustrates continuous solid 
phase diagram [19] 
 
 
 
 
 
 
Figure 2: Continuous solid phase diagram 
 
 
Fig 2: Continuous solid phase diagram 
Discontinuous solid solutions: In this case, the 
solubility of each of component is limited. One of the 
solid components is completely dissolved in the other 
solid component. Note that below a certain 
temperature, the mutual solubilities of two components 
start to decrease. Due to practical considerations it has 
been suggested by Goldberg (1964) that the term solid 
solution should only be applied when mutual solubility 
of two components exceeds 5%. Whether or not a 
given solid solution can be utilized as a dosage form, 
strategy will depend not only on mutual solubility of 
two components but also on dose of drug 
component[12] 
3. On the basis of distribution in solvendum 
According to the way in which solvent molecules are 
distributed in solvendum: 
Glass solutions: Chiou and Riegelman first proposed 
the idea of creating glassy solid solution as a method to 
increase solubility and absorption of a substance. 
Glassy state is seen as critical and decisive for 
durability and physical stability of incorporated 
lipophillic substance. Glassy solid solutions is a multi-
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ingredient, glassy system, which consist of one phase 
only. At the molecular level it is homogeneous and 
uniform. The carrier in this system occurs in 
amorphous state, while the dissolved molecules are 
molecularly dispersed [22].   
Amorphous solid solutions: 
The drug with propensity to super cooling has more 
tendency to solidify as an amorphous form in presence 
of carrier [6].This method is similar to simple eutectic 
mixtures but the only difference is that the drug is 
precipitated in amorphous form [23,24]. 
Substitutional crystalline solid solutions:In this type 
of solid solution the solute molecules act as substitutes 
(in crystal lattice of solid solvent) for the solvent 
molecule continuous and discontinuous solid solutions 
can be prepared by this method. As possible the size of 
solute and solvent are of similar dimension ([20, 21]. 
Interstitial crystalline solid solutions:In this type of 
solid solution, the solute (guest) molecule occupies the 
interstitial space of solvent (host) lattice. It usually 
forms only a discontinuous solid state (10). The solute 
molecule should have a molecular diameter not more 
than 0.59 of the solvent molecule's molecular diameter. 
The volume of the solute molecules should be less than 
20% of the solvent [25, 26]. The distribution of solute 
molecule in solvent in interstitial solvent system is 
shown in figure 3 [19]. 
 
 
 
 
 
 
 
 
 
 
Fig 3: Interstitial solid solution 
Amorphous  precipitation in crystalline matrix: 
Instead of forming a simple eutectic mixture in which 
both the drug and the carrier crystallize simultaneously 
from a melting or a solvent method of preparation, the 
drug may also precipitate in precipitate out in an 
amorphous form in crystalline carrier. Since the 
amorphous form is the highest energy form of a pure 
drug, it should under almost all conditions, produce 
faster dissolution and absorption rates than the 
crystalline form whether the crystals are or are not 
dispersed in carrier [10]. Figure 4 shows the 
distribution in amorphous solutions [19]. 
 
 
 
 
 
 
 
Fig 4: Amorphous solutions  
 
Biopharmaceutical classification system 
Biopharmaceutical Classification System (BCS) is a 
guiding tool for a strategy to improve the efficacy of 
drug development by proper selection of dosage form. 
The BCS, introduced by Amidon et al is a scientific 
framework for classifying a drug depending on in vitro 
solubility and in vivo permeability [27-30]. In the BCS, 
Class II drugs are those with high membrane 
permeability and low aqueous solubility, therefore, 
they are the ideal candidate for solid dispersion 
technologies for improving the solubility and 
bioavailability(Table 3) 
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Table 3: Biopharmaceutical classification system 
Class Permeability Solubility Salient Features Examples Reference 
I High High These compounds are well absorbed and their 
absorption rate is usually higher than excretion 
No herbs are classified 
entirely as class I 
29 
II High Low The bioavailability of these products is limited by 
solvation rate. A correlation between in vivo 
bioavailability and in vitro solvation can be found 
Zingiberofficinale, 
Curcumin longa 
29, 31 
 
III 
Low High The absorption is limited by permeation rate but 
the drug is solvated very fast 
Ginkgo bilabo, Allium 
sativum, Cassia senna,  
Milk thistle 
29 
IV Low Low These have poor bioavailability. They are not well 
absorbed over intestinal mucosa and high 
variability is expected 
Panax ginseng, 
Glycyrrhizaglabra 
29 
 
Advantages of solid dispersions: 
The solid dispersions provides the myriad spectrum of 
desired characteristics for effective delivery of 
phytoconstituents [30-32] 
 Amorphous state of drug leads to enhancement in 
drug release. 
 Improved wettability results in increased 
solubility. 
 Presystemic metabolism is reduced due to increase 
in dissolution rate and absorption. Particles having 
higher porosity. Increase in porosity influence 
carrier properties and increase drug release profile. 
 By changing water solubility drug bioavailability 
can be increased. 
 Lower doses of the drugs are required due to rapid 
dissolution that results in increase in rate and 
extent of absorption. 
 Liquid form of drug can be transferred in solid 
form. 
 Particle size reduction in solid dispersion leads to 
increase surface area which causes increase in 
dissolution rate hence bioavailability is improved. 
 Preferred by patients in comparison to liquid 
solubilisation products. 
Limitations of solid dispersions  
The limitations of solid dispersions technology have 
been a drawback for their commercialization [33-36]. 
These are enumerated in the following section: 
 Expensive and laborious methods. .  
 Tackiness property of solid dispersions make it 
difficult to handle. 
 Large amount of carrier is required to achieve good 
dissolution. 
 During storage of solid dispersions many problems 
encountered which are phase separation, conversion 
of amorphous to crystalline form and crystal growth 
due to which decrease in solubility, dissolution and 
bioavailability occurs. 
Carriers used in solid dispersions [32,14] 
The choice of carrier has a enormous impact on 
success rate of the solid dispersion strategy. The 
suitable characteristics of a carrier used are enlisted 
below: 
 They should be non toxic 
 High water solubility - improve wettability and 
enhance dissolution. 
 Soluble in common solvent with drug - solvent 
evaporation. 
 High glass transition point - improve stability. 
 Relatively low melting point - melting process. 
 Minimal water uptake. 
 Low vapour pressure 
 Capable of forming a solid solution with the drug - 
similar solubility parameter. 
 
Table 4: Carriers used in solid dispersion [6, 37] 
S. No.   Carriers Nature 
1. Dextrose, Sorbitol, Mannitol, Lactose, Sucrose, Galactose, Maltose  Sugar 
2. Succinic acids, Citric acids Acids 
3. Polyethylene Glycol, Povidone, Hydroxy Ethyl Cellulose,  Hydroxyl 
Propyl  Methyl Cellulose, Galactomannan, Pectine   
Polymeric material 
4. Eudragit RS, Hydroxy Propyl Methyl Cellulose, Pthalate  Insoluble or Enteric Polymers 
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5. Poloxamer 188, Spans, Polyoxyethylene Stearate, Renex, Texofor, 
Tweens, Deoxycholioc acid  
Surfactants 
6. Sodium acetate, Ascorbic acid, Sodium-p-hydroxybenzoate,Sodium-o-
hyroxy benzoate, Resorcinol, Sodium citrate  
Hydrotropes 
7. Starburst, Polyamidoamine  Dendrimers 
8. Hydroxyalkylxanthines, Urea, Urethans Miscellaneous 
 
Solvent selection for solid dispersion system: 
In order to prepare solid dispersion, solvents should be 
selected on the basis of following criteria: (32, 34).  
 Dissolve both drug and carrier 
 Water based systems preferable 
 Toxic solvents to be avoided due to the risk of 
residual levels after preparation e.g. chloroform and 
dichloromethane 
 Use of surfactants to create carrier drug solutions 
but care should be taken as they can reduce the 
glass transition point 
 Ethanol is a less toxic alternative 
 
Table 5: Solvents used in solid dispersion 
Class Solvents Feature 
Class I Benzene 
Carbon tetrachloride 
1,2- dichloroethane 
1,1- dichloroethane 
1,1,1- trichloroethane 
Solvents to be avoided due to their deleterious environmental effect 
Class II Chloroform 
Ethylene glycol 
Methanol 
Pyridine 
Toluene 
Should be limited in pharmaceutical products because of their 
inherent toxicity 
Class III Acetic acid,Acetone 
Formic acid 
Ethyl ether 
Propyl acetate 
Less toxic and of lower risk to human health and should be limited by 
GMP or other quality based requirements 
Class IV Petroleum ether 
Isopropyl ether 
 
Solvents for which no adequate  toxicological data was found and are 
of interest to manufacturers of drug products 
 
Manufacturing process: The subsequent section is a 
brief preface of the various techniques widely accepted 
to deal with the challenges of administering natural 
drugs, tackled by formulating solid dispersions. 
 Melting (fusion method) 
In this method, the mobility of carrier is high enough to 
change drug incorporation. In general, heating all 
components above their melting or glass transition 
temperatures, followed by mixing and cooling is 
'melting method'.  The uniformly mixed melted mass is 
allowed to cool at room temperature or under cool 
conditions. The cooling rate may have great impact on 
characteristics and stability of solid dispersions. For 
cooling and solidification process, ice bath agitation, 
solidification on petri dishes at room temperature 
inside a dessicator, spreading on plates placed over dry 
ice, immersion in liquid nitrogen or stored in dessicator 
were used. The most important requirement of this 
method is that drug and carrier should be stable at 
room temperature. 
 The method is advantageous due to its simplicity and 
economy. In addition, a super saturation of a solute or 
drug in a system can often be obtained by quenching 
the melt rapidly from a high temperature.  
The major disadvantage of this method is that the 
texture of solid dispersion after cooling is very hard. 
Therefore, size reduction is difficult [38-43]. 
 Solvent method 
Solvent method was first applied to the preparation of 
solid dispersions by Tachibana and Nakamura [18]. 
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This method aims to dissolve the drug and carrier 
simultaneously in a common solvent, followed by 
removal of solvent by evaporation. Solvent is allowed 
to evaporate by various processes including vacuum 
drying, heating on a hot plate, using rotary evaporator, 
a stream of nitrogen, spray drying, freeze drying and 
using supercritical fluids. To minimize the drug 
particle size in solid dispersion, the drug and matrix 
have to be dispersed in the solvent as fine as possible, 
preferably drug and matrix material are in dissolved 
state in one solution. 
The main advantage of this method is that thermal 
decomposition of drugs or carrier can be prevented 
because of the low temperature required for the 
evaporation of organic solvents [10]. 
 The major challenge in preparation of solid dispersion 
by solid evaporation method is selection of a common 
solvent to dissolve drug as well as carrier and to mix 
both the drug and the matrix in one solution, which is 
difficult when they differ significantly in polarity [44-
48].  
 Melting solvent method 
The combination of melting method and solvent 
evaporation method is melting solvent method. It is 
performed by dissolving the drug in suitable solvent 
and mixing of this solution with the molten carrier 
followed by cooling, resulting in solidification [49]. 
Such a unique method possess the advantages of both 
the melting and solvent methods. Unfortunately, from a 
practical standpoint, it is only limited to drugs with low 
therapeutic dose, e.g. Below 50 mg [10]. 
 Hot melt extrution method 
Hot melt extrution method is useful in preparation of 
solid dispersions in single step. It is a combination of 
melting and a mechanical process in which a drug, 
polymer and optionally plasticizer are mixed and 
melted under controlled condition of temperature and 
shear forces. The mass of co-melts is mixed with the 
help of transport screws and extruded through a die 
plate, yielding solid dispersions. The advantage of this 
method is that it has the potential of providing the 
shape to the heated drug-mixture into implants, 
ophthalmic inserts, or oral dosage forms. Metrex® 
process is a technology based on hot melt extrusions 
applied for development of a ritonavir - lopinavir 
combination tablet with improved dissolution. Another 
recently developed technology is Meltdose® for 
improved dissolution of fenofibrate [50-53]. Figure 5 is 
the schematic representation of components of a single 
screw melt extruder [19]  
 
 
 
 
 
 
 
 
 
Fig 5 Schematic diagram showing components of a single screw melt extruder 
Spray drying method 
With tremendous development in spray drying process, 
it has emerged as a highly versatile technique 
operational in variety of industrial process such as food 
and dairy processing, ceramics, paints, fertilizers, 
detergents and pharmaceutical field. In this method 
drug and carrier are evaporated by spraying the 
solution as fine droplets into a chamber under 
controlled conditions of heat, humidity and air flow. It 
is cheap, fast and a one-step process and is widely used 
for processing solutions, emulsion, suspensions and 
manufacturing of solid dispersions.  But the 
formulation of sticky product at outlet may occur, 
which adheres to the walls. This occurs due to high 
residual solvent which act as plasticizer and decrease 
glass transition temperature or the outlet temperature of 
the cyclone system [54-57]. 
 Kneading method 
The physical mixture of drug and carrier is triturated to 
thick paste using small volume of solvent. The solvent 
used can be organic (alcohol, dichloromethane, 
acetone) or aqueous or mixture. The kneaded paste is 
dried in oven and the dried mass is pulverized and 
stored in desiccators. Kneading process is economical 
but residual solvent may be an issue [41]. 
 Freeze drying 
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Freeze drying consist of three successive steps: 
freezing, primary drying and secondary drying. A 
sample to be freeze dried consists of drug, excipients 
and one or more solvents.  High freeze rates can be 
achieved by spray freezing on cryogenic liquid surface, 
or into cryogenic liquid, followed by freeze drying. In 
this method, the small frozen droplets are produced by 
spraying or atomizing drug-carrier solution or 
suspension into cryogenic liquid such as liquid 
nitrogen. The resulting frozen droplets are freeze dried 
in a conventional freeze dryer. It is advantageous for 
processing of thermolabile material but also has a 
disadvantage of being lengthy and expensive process 
(41, 61).  
 
 
 
 
Detection of crystallinity in solid dispersions [58-60] 
Several different molecular structures of the drug in the 
matrix can be encountered in solid dispersions (Figure 
1.7). Many attempts have been made to investigate the 
molecular arrangement in solid dispersions. However, 
most effort has been put in discrimination between 
amorphous and crystalline material. Consequently, for 
that purpose many techniques are available which 
detect the amount of crystalline material in the 
dispersion. The amount of amorphous material is never 
measured directly but is mostly derived from the 
amount of crystalline material in sample. It should be 
noted that through the assessment of crystallinity as 
method to determine the amount of amorphous drug it 
will not be revealed whether the drug is present as 
amorphous drug particles or as molecularly dispersed 
molecules e.g. solid dispersions of type II or III and V 
or VI. 
 
Fig 7: Schematic representation of three modes of incorporation of drug in a solid dispersion 
 
Currently, the following techniques are available to 
detect (the degree of) crystallinity: 
1. Powder X-ray diffraction can be used to 
qualitatively detect material with long range 
order. Sharper diffraction peaks indicate more 
crystalline material. Recently developed X- ray 
equipment is semi-quantative. 
2. Infrared spectroscopy (IR) can be used to detect 
the variation in the energy distribution of 
interactions between drug and matrix. Sharp 
vibrational bands indicate crystallinity. Fourier 
Transformed Infrared spectroscopy (FTIR) was 
used to accurately detect crystallinities ranging 
from 1 to 99 % in pure material. However in solid 
dispersions only qualitative detection was 
possible. 
3. Water vapour sorption can be used to discriminate 
between amorphous and crystalline material when 
the hygroscopicity of both completely crystalline 
and completely amorphous samples. In some 
studies, amorphous materials were plasticized by 
water sorption and crystallized during the 
experiment. However, crystallization can be 
accompanied by expel of water depending on the 
degree of hydration of crystalline material. In this 
case, the loss of water is used to calculate the 
amount of amorphous material. 
However, water vapour sorption in a binary 
mixture, e.g. solid dispersions, can be much more 
complicated than in pure materials, firstly because 
water sorption is not always proportional to the 
composition of a binary intimately mixed system. 
the second complication is that matrix or drug 
crystallization during water vapour sorption is 
often not complete within the experimental time 
scale due to sterical hindrance and proceeds to an 
unknown extent. 
4.  Isothermal microcalorimetry measures the 
crystallization energy of amorphous material that 
is heated above its Tg. However, this technique has 
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some limitations.  First, this technique can only be 
applied if the physical stability is such that only 
during the measurement, crystallization takes 
place. Secondly, it has to be assumed that all 
amorphous material crystallizes. Thirdly, in a 
binary mixture of two amorphous compounds a 
distinction between crystallization energies of drug 
and matrix is difficult. 
5.  Dissolution calorimetry measures the energy of 
dissolution, which is dependent on the crystallinity 
of the sample. Usually, dissolution of crystalline 
material is endothermic, whereas dissolution of 
amorphous material is exothermic. The dissolution 
energies of the two components in both crystalline 
and amorphous state should be determined in 
separate experiments in order to use this technique 
quantitatively. However, also drug-matrix 
interactions will contribute to the dissolution 
energy of the solid dispersion. 
6.  Macroscopic techniques that measure mechanical 
properties that are different for amorphous and 
crystalline material can be indicative for degree of 
crystallinity. Density measurements and dynamic 
mechanical analysis (DMA) determine the 
modulus of elasticity and viscosity and thus 
affected by the degree of crystallinity. 
However, also these techniques require knowledge 
about the additivity of these properties in 
intimately mixed binary solids. 
7.  The extent of supersaturation during dissolution 
experiments of solid dispersions are sometimes 
correlated to the mode of incorporation of drug. It 
is unmistakable that the mode of incorporation 
largely determines the dissolution behaviour, but 
knowledge about dissolution behavior is too poor 
to draw any conclusions from dissolution 
experiments, because it cannot be excluded that 
during dissolution crystallization of drug occurs. 
8. A frequently used technique to detect the amount of 
crystalline material is Differential Scanning 
Colorimetry (DSC). In DSC, samples are heated 
with a constant heating rate and amount of energy 
necessary for that is detected. With DSC the 
temperatures at which thermal events occur can be 
detected. Thermal events can be a glass to rubber 
transition, recrystallization, melting or 
degradation. If during DSC measurements, 
amorphous material crystallizes, information is 
obtained on the crystallization kinetics and on the 
physical stability of the amorphous sample. To 
quantify the amount of crystalline material, 
measurements should be completed before 
crystallization of amorphous material has started. 
In some cases, this can be established applying 
high scanning rates. 
 
 Fig 8: Physical changes in solid dispersions resulting in crystallization 
Clearly many techniques can distinct between the crystalline and amorphous state for pure materials. However, in a 
mixture of two components, like in solid dispersion, it is always necessary to know the interaction between the 
individual components and the effect thereof on the physical property that is being quantified and from which 
crystallinity is to be derived [12, 36]. 
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Table 6: List of drugs already used in the form of solid dispersions, along with type of polymers and 
methods employed [61-93] 
S. No. Drug Polymer Method 
1. CefiximeTrihydrate Urea  Solvent evaporation method 
2. Gliclazide PEG 8000 and PEG 6000 Fusion- Solvent Techniques 
3. Celecoxib PEG 6000 and PVP K 30 Kneading and solvent evaporation 
method 
4. Glyburide PEG 4000 and PEG 6000 Lyophilization techniques 
5. Allopurinol Gelucire50/ 13 Physical mixing, solvent evaporation, 
kneading and closed melting method 
6. Azithromycin 
Dihydrate 
Urea Solvent evaporation method 
7. Itraconazole PEG 6000 and 
polyvidonevinylacetate 
Spray drying 
8. Meloxicam Hydroxyethylcellulose, mannitol and 
PEG 4000  
Solvent evaporation, melting and 
melting solvent method 
9. Lansoprazole PEG 4000 and amphiphlic polymer 
Soluplus
®
 
Solvent evaporation method 
10. Satranidazole PVP K30 and PEG 4000 Solvent evaporation method 
11 Nimodipine HPMC Spray drying method 
12 indomethacin Gelucire 50/13 and PEG4000 Hot melting method 
13 Curcumin HPMC 4000, HPMC 6 and PEO Melting method 
14 Carbamazepine PVP K30, either Gelucire 44/14 or 
Vitamin E TPGS 
Conventional solvent evaporation and 
supercritical methods 
15 Carbamazepine HPMC Hot-melt extrusion 
16 Carvedilol Beta cyclodextrin and 
Hydroxypropyl-cyclodextrin 
Solvent evaporation methods 
17 Rofecoxib Poloxamer 188 Melting method 
18 Carvedilol PEG 6000, poloxamer 407, HPMC 
and Na-starch Glycolate 
Fusion and solvent evaporation 
method 
19 Mefenamic acid PVP K30, HPMC and PEG Solvent evaporation method 
20 Carvedilol HPβCD and tartaric acid Kneading technique 
21 Itraconazole PVPVA 64, PVP K25, PEG 6000 
and HPMC 2910 E5 
Spray drying 
22 Glipizide PEG 4000 Melt mixing method 
23 Ibuprofen PEG, Talc and PEG-Talc Solvent evaporation method 
24 Glipizide Poloxamer 188 and Poloxamer 407 Kneading method 
25 Furosemide Microcrystalline cellulose Cogrinding method 
26 Curcumin HPMC K 4M and HPMC K 15M. Solvent change precipitation method 
27 Valsartan Poloxamer 188 Melting method 
28 Nisoldipine HPC and PVP K 29/32 Solvent method 
29 Lacidipine  PEG 4000, PEG 6000, Hydroxy 
ethyl cellulose and Dextrin 
Solvent evaporation method 
30 Aceclofenac  Avicel 200 and Sylysia 350 Kneading method 
31 Valsartan Poloxamer 407 Melting method 
32 Metformin HCl Eudragit RLPO, Eudragit RSPO, 
HPMC K100 and compritol ATO 
888 
Solvent evaporation method 
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Conclusion 
 
One of the most challenging problems in 
pharmaceutical field is to increase the bioavailability of 
orally administered poorly water soluble drug. The 
various techniques described above alone or in 
combination can be used to enhance the solubility of 
the drug, proper selection of solubility enhancement 
method is the key to ensure the goals oral 
bioavailability. Solid dispersion technology extremely 
helps in improving the dissolution property of poorly 
water soluble drugs. Various techniques described in 
this review are successfully used for the preparation of 
solid dispersions in the bench and lab scale and can be 
used as industrial scale also. 
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